Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Magnani CF"'
Autor:
Vago L, Terlizzi SD, Zino E, Magnani CF, Stanghellini MTL, Magnani Z, Mazzi B, Clerici D, BONDANZA , ATTILIO, Bregni M, Rossini S, Peccatori J, BONINI , MARIA CHIARA, CICERI , FABIO, BORDIGNON, CLAUDIO, Fleischhauer K.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10495::7e083f13fca386e99fe0b9a77733b802
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Clelia Di Serio, Mauro Pala, Rosa Bacchetta, Silvia Gregori, Leonie Brockmann, Nicola Gagliani, Richard A. Flavell, Filippo Trentini, Samuel Huber, Paula Licona-Limón, Chiara F. Magnani, Marco Andreani, Monica E. Gianolini, Maria Grazia Roncarolo, Binggege Guo, Alessandro Bulfone, De'Broski R. Herbert
Publikováno v:
Nature Medicine. 19:739-746
CD4+ type 1 T regulatory (Tr1) cells are induced in the periphery and have a pivotal role in promoting and maintaining tolerance. The absence of surface markers that uniquely identify Tr1 cells has limited their study and clinical applications. By ge
Autor:
Eugenio Montini, Andrea Calabria, Chiara F. Magnani, Sarah Tettamanti, Laurence J.N. Cooper, Alessandro Aiuti, Fabrizio Benedicenti, Erika Tenderini, Greta Maria Paola Giordano Attianese, Ettore Biagi, Nice Turazzi, Andrea Biondi
Publikováno v:
Oncotarget
// Chiara F. Magnani 1 , Nice Turazzi 1 , Fabrizio Benedicenti 2 , Andrea Calabria 2 , Erika Tenderini 2 , Sarah Tettamanti 1 , Greta M.P. Giordano Attianese 1, 3 , Laurence J.N. Cooper 3 , Alessandro Aiuti 2 , Eugenio Montini 2 , Andrea Biondi 1 , E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1183c393c6ec1766d3bea78cc0c18af
Autor:
Ehud Hauben, Valentina Pacciani, Silvia Gregori, Daniela Tomasoni, Maria Grazia Roncarolo, Manuela Battaglia, Miriam Scirpoli, Chiara F. Magnani
Publikováno v:
Blood. 116(6)
Type 1 T regulatory (Tr1) cells suppress immune responses in vivo and in vitro and play a key role in maintaining tolerance to self- and non–self-antigens. Interleukin-10 (IL-10) is the crucial driving factor for Tr1 cell differentiation, but the m
Publikováno v:
Human immunology. 70(12)
Adaptive type I regulatory T (Tr1) cells are suppressor cells characterized by the production of interleukin (IL)-10 in the absence of IL-4. IL-10 is essential not only for suppression of effector cells by Tr1 cells, but also for their differentiatio
Autor:
Volta L; Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Myburgh R; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Pellegrino C; Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Koch C; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland., Maurer M; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Manfredi F; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Hofstetter M; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Kaiser A; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Schneiter F; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland., Müller J; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Buehler MM; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland., De Luca R; Philochem AG, Otelfingen, Switzerland., Favalli N; Philochem AG, Otelfingen, Switzerland., Magnani CF; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich (CCCZ), Zurich, Switzerland., Schroeder T; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland., Neri D; Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.; Philochem AG, Otelfingen, Switzerland., Manz MG; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. markus.manz@usz.ch.; Comprehensive Cancer Center Zurich (CCCZ), Zurich, Switzerland. markus.manz@usz.ch.
Publikováno v:
Leukemia [Leukemia] 2024 Sep 18. Date of Electronic Publication: 2024 Sep 18.
Autor:
Magnani CF, Myburgh R, Brunn S, Chambovey M, Ponzo M, Volta L, Manfredi F, Pellegrino C, Pascolo S, Miskey C, Sandoval-Villegas N, Ivics Z, Shizuru JA, Neri D, Manz MG
Publikováno v:
Molecular therapy oncolytics [Mol Ther Oncolytics] 2023 Aug 20; Vol. 30, pp. 150. Date of Electronic Publication: 2023 Aug 20 (Print Publication: 2023).
Autor:
Magnani CF; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), 8091 Zurich, Switzerland., Myburgh R; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), 8091 Zurich, Switzerland., Brunn S; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), 8091 Zurich, Switzerland., Chambovey M; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), 8091 Zurich, Switzerland., Ponzo M; Tettamanti Center, Fondazione IRCCS San Gerardo Dei Tintori, 20900 Monza, Italy., Volta L; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), 8091 Zurich, Switzerland., Manfredi F; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), 8091 Zurich, Switzerland., Pellegrino C; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), 8091 Zurich, Switzerland., Pascolo S; Department of Dermatology, University Hospital Zurich and University of Zurich, 8091 Zurich, Switzerland., Miskey C; Division of Medical Biotechnology, Paul-Ehrlich-Institute, 63225 Langen, Germany., Ivics Z; Division of Medical Biotechnology, Paul-Ehrlich-Institute, 63225 Langen, Germany., Shizuru JA; Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA 94305, USA., Neri D; Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, 8093 ETH Zurich, Switzerland., Manz MG; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), 8091 Zurich, Switzerland.
Publikováno v:
Molecular therapy oncolytics [Mol Ther Oncolytics] 2023 Jul 19; Vol. 30, pp. 56-71. Date of Electronic Publication: 2023 Jul 19 (Print Publication: 2023).
Autor:
Moretti A; Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca/Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), Monza, Italy., Ponzo M; Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca/Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), Monza, Italy., Nicolette CA; CoImmune Inc., Durham, NC, United States., Tcherepanova IY; CoImmune Inc., Durham, NC, United States., Biondi A; Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca/Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), Monza, Italy.; Department of Pediatrics, University of Milano - Bicocca, Milan, Italy.; Clinica Pediatrica, University of Milano - Bicocca/Fondazione MBBM, Monza, Italy., Magnani CF; Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca/Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), Monza, Italy.; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Publikováno v:
Frontiers in immunology [Front Immunol] 2022 Jun 09; Vol. 13, pp. 867013. Date of Electronic Publication: 2022 Jun 09 (Print Publication: 2022).